Search Results
Results found for "Chris Evans"
- Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands..
October 2022 Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics optimized approach of combining the data derived from steered molecular dynamics simulations and the Bell-Evans
- Why Sokhom Pin Never Left GPCRs, Even When Everyone Else Did
But Sokhom Pin stayed loyal to GPCRs , even when big pharma turned its gaze to other targets like kinases
- The Imprecision Problem: Why Your GPCR Drug Discovery Program Is Off-Track Before It Even Starts
But here’s the reality: even ultra-specialized experts can’t fix systemic dysfunction in their spare Even flawless experiments collapse under sloppy systems. data management pipeline, teams waste hours cleaning, reconciling, and integrating before they can even
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
Chris Cargill appointed as President and Chief Executive Officer • Dr.
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris
- 📰 GPCR Weekly News, October 9 to 15, 2023
success Sosei and PharmEnable extend neurological disease drugs hunt Sosei Heptares’ President & CEO Chris
- 📰 GPCR Weekly News
INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease Chris
- 📰 GPCR Weekly News, October 16 to 22, 2023
Topline Safety and Tolerability Data from Proof-of-Concept Studies Sosei Heptares’ President & CEO Chris
- 📰 GPCR Weekly News, February 13 to 19, 2023
From the scientist’s view: a conversation with … Chris Tate AI is dreaming up drugs that no one has ever
- Unlocking the Future of Medicine: Advancements in GPCR Research
This week's highlight includes congrats to Omolade Otun, Chris de Graaf, Cherine Bechara, et al. for
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Cary, B.P., et al., New Insights into the Structure and Function of Class B1 GPCRs.
- Nanobodies: New Dimensions in GPCR Signaling Research
G., Choi, H. J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D.
- From Student to Mentor: What Alessandro Nicoli Learned About Leading in Science
Antonella Di Pizio’s lab , there was almost nothing—no team, no culture, not even proper desks. responsibilities: from building computational models of GPCRs to guiding interns, master’s students, and even “I remember my first day—we were even sharing the desk.
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
small molecules, lipids, receptor-activity modifying proteins, autoantibodies, membrane stretch, and even the strongest coupling partner Gαs (Figure 2A), and for the glucagon-like-peptide-1 receptor (GLP-1R) even van der Westhuizen ET, Valant C, Sexton PM, Christopoulos A. Manchanda Y, ElEid L, Oqua AI, Ramchunder Z, Choi J, Shchepinova MM, et al. Why even physicists still don't understand quantum theory 100 years on.
- From GPCR Data Chaos to Decisive Action
Is Your GPCR Program Slowing Down—Even With Good Data? You’re not alone. I call it the Lego Bucket Problem : You’ve got CRO output, internal assay data, maybe even some promising calendly.com/drgpcr/yamina-corner Or explore how we can work together: 👉 Yamina.org 🔑 Key Takeaways ✅ Even
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
But if the antagonist binds tightly and dissociates slowly, the receptor remains blocked, even at high This mimics non-competitive behavior, even if the antagonist occupies the orthosteric site. Antagonist “hogs” the receptor, depressing the response, even if more agonist is added.
- Is Your Agonist Really “Working”—Or Are You Just Seeing What Your System Allows?
Through powerful analogies (think batteries and balance scales), Terry reveals why different tissues—and even
- From Ox Liver to AI: How the History of Pharmacology Shapes Its Future
And yes, you'll even meet the man who turned failed experiments into a Nobel Prize-winning discovery
- Antibodies That Don’t Block, They Activate: A New Angle on Autoimmunity and GPCRs
system is not just used for detection, but for functional screening : add ligands, track modulation, and even
- From Pharmacy Crisis to Scientific Calling: Catherine Demery’s Unfiltered Path into Opioid Research
Catherine’s methodical retention of those skills later gave her a solid foundation in her academic work, even from doing the work The most impactful science is often personal Technical discipline is transferable—even
- The Chemistry of Confidence: Aha Moments That Shape Scientific Careers
, her early decisions were based on curiosity, instinct, and a surprising love of cooking (yes, she even
- Pepducin-mediated G Protein-Coupled Receptor Signaling in the Cardiovascular System
activity in an orthosteric site-independent manner to compounds with therapeutic potential that have even antagonist, partial agonist, and biased agonist outcomes in various primary and clonal cell systems, with even
- From Technician to Trailblazer: How Sokhom Pin Designed His Own PhD Program While Working in Industry
How It Worked BMS funded the research, salary, and even tuition UConn accepted the research done in the
- Are You Guessing or Forecasting? Master GPCR Pharmacologic Models Before It’s Too Late
🔹 Elevate your strategy → Building clarity in GPCR drug discovery Even the strongest GPCR programs
- X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
July 2022 "Not even a PIPE financing could save X4 Pharmaceuticals from enacting layoffs and trimming
- The Quiet Power of RGS Proteins: Rethinking Pain Pathways through GPCR Biology
GPCRs in the Background, But Always Present Even though his primary focus wasn’t GPCRs themselves, Serafini
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
Learn to leverage restricted diffusion and rebinding to create drugs with longer therapeutic coverage, even distinguish between active and inactive ligands, paving the way for computational ligand discovery even
- Pharmacology at Your Fingertips: Terry’s Corner Launches
Because even the best data means nothing without structure. That’s the Lego Bucket Problem.
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
reasons why researchers typically require years to uncover the mechanisms of disease before they can even
- Serotonin Receptor 5-HT2A Regulates TrkB Receptor Function in Heteroreceptor Complexes
Heterodimerization decreased TrkB autophosphorylation, preventing its activation with agonist 7,8-DHF, even